Giuseppina D'Amato Selected Research

Anti-Bacterial Agents (Antibiotics)

9/2005	In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients.
3/2005	In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients.
2/2005	Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock.
2/2005	RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.
12/2004	The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis.
7/2004	Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis.
7/2004	A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giuseppina D'Amato Research Topics

Disease

8	Sepsis (Septicemia) 09/2005 - 11/2003
6	Infections 09/2005 - 08/2003
6	Septic Shock (Toxic Shock Syndrome) 02/2005 - 06/2003
3	Staphylococcal Infections 12/2004 - 10/2003
2	Shock 02/2005 - 02/2004
1	Pneumonia (Pneumonitis) 03/2005
1	Bacteremia 02/2005
1	Necrosis 09/2004
1	Body Weight (Weight, Body) 07/2004

Drug/Important Bio-Agent (IBA)

7	Anti-Bacterial Agents (Antibiotics)IBA 09/2005 - 07/2004
4	EndotoxinsIBA 09/2004 - 06/2003
4	Peptides (Polypeptides)IBA 07/2004 - 06/2003
3	pexigananIBA 09/2005 - 09/2004
3	GlycopeptidesIBA 08/2004 - 08/2003
3	LipopolysaccharidesIBA 02/2004 - 06/2003
2	HistatinsIBA 03/2005 - 07/2004
2	MagaininsIBA 02/2005 - 09/2004
2	RNAIII inhibiting peptideIBA 02/2005 - 08/2003
2	Vancomycin FDA LinkGeneric 02/2005 - 10/2003
2	CathelicidinsIBA 12/2004 - 01/2004
2	Linezolid (Zyvox)FDA Link 08/2004 - 10/2003
2	temporinIBA 08/2004 - 08/2003
2	Imipenem FDA Link 07/2004 - 02/2004
2	Piperacillin FDA LinkGeneric 02/2004 - 11/2003
2	Polyethylene Terephthalates (Polyethylene Terephthalate)IBA 10/2003 - 08/2003
1	ExotoxinsIBA 02/2005
1	BMAP-28IBA 12/2004
1	Antimicrobial PeptidesIBA 12/2004
1	Anti-Infective Agents (Microbicides)IBA 12/2004
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2004
1	Sodium Chloride FDA LinkGeneric 07/2004
1	P-113DIBA 07/2004
1	Polymyxin B (Aerosporin)FDA LinkGeneric 07/2004
1	SolutionsIBA 07/2004
1	RNA (Ribonucleic Acid)IBA 07/2004
1	dermaseptinIBA 07/2004
1	Pharmaceutical PreparationsIBA 07/2004
1	Insecta cecropin B proteinIBA 02/2004
1	antimicrobial peptide IB-367 (iseganan)IBA 11/2003
1	Levofloxacin (Levaquin)FDA Link 10/2003
1	AgarIBA 08/2003
1	Biocompatible Materials (Biomaterials)IBA 08/2003
1	Staphylococcus aureus RNAIIIIBA 08/2003
1	Proteins (Proteins, Gene)FDA Link 08/2003
1	Proline (L-Proline)FDA Link 06/2003

Therapy/Procedure

5	Ligation 02/2005 - 11/2003
5	Punctures 02/2005 - 11/2003
3	Intraperitoneal Injections 09/2004 - 11/2003
2	Prostheses and Implants (Prosthesis) 10/2003 - 08/2003
1	Surgical Amputation (Amputations) 08/2003